State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China.
Key Laboratory of Synthetic and Biological Colloids (Ministry of Education), School of Chemical and Materials Engineering, Jiangnan University, Wuxi, China.
J Sci Food Agric. 2020 Aug;100(10):3841-3849. doi: 10.1002/jsfa.10421. Epub 2020 May 8.
Stevia has been proposed as a potential antidiabetic sweetener, mainly based on inconsistent results from stevioside or the plant extract, yet lacking relative experimental evidence from individual steviol glycosides (SGs) and their metabolites.
The results systematically revealed that the typical SGs and their final metabolite (steviol) presented an antidiabetic effect on streptozotocin (STZ) diabetic mice in all assayed antidiabetic aspects. In general, the performance strength of the samples followed the sequence steviol > steviol glucosyl ester > steviolbioside > rubusoside > stevioside > rebaudioside A, which is opposite to their sweetness strength order, and generally in accordance with the glucosyl group numbers in their molecules. This may imply that the antidiabetic effect of the SGs might be achieved through steviol, which presented antidiabetic performance similar to that of metformin with a dose of 1/20 that of metformin. Moreover, the F-fluorodeoxyglucose traced micro-PET experiment revealed that stevioside and steviol could increase the uptake of glucose in the myocardium and brain of the diabetic mice within 60 min, and decrease the accumulation of glucose in the liver and kidney.
The SGs and steviol presented an antidiabetic effect on STZ diabetic mice in all assayed aspects, with an induction time to start the effect of the SGs. Stevioside and steviol could increase uptake of glucose in the myocardium and brain of the diabetic mice, and decrease accumulation of glucose in the liver and kidney. The performance strength of the SGs is generally in accordance with glucosyl group numbers in their molecules.
甜菊糖已被提议作为一种有潜力的抗糖尿病甜味剂，主要基于甜菊苷或植物提取物的不一致结果，但缺乏来自单个甜菊醇糖苷（SGs）及其代谢物的相关实验证据。
结果系统地揭示了典型的 SGs 及其最终代谢产物（甜菊醇）在所有测定的抗糖尿病方面对链脲佐菌素（STZ）糖尿病小鼠均表现出抗糖尿病作用。总的来说，样品的性能强度遵循以下顺序：甜菊醇>甜菊糖苷葡萄糖酯>甜菊双糖苷>毛蕊花糖苷>甜菊苷>莱鲍迪苷 A，这与它们的甜度强度顺序相反，通常与它们分子中的葡萄糖基数量一致。这可能意味着 SGs 的抗糖尿病作用可能是通过甜菊醇实现的，其抗糖尿病性能类似于二甲双胍，剂量为二甲双胍的 1/20。此外，F-氟脱氧葡萄糖示踪微 PET 实验表明，甜菊苷和甜菊醇可在 60 分钟内增加糖尿病小鼠心肌和脑组织对葡萄糖的摄取，并减少肝脏和肾脏中葡萄糖的积累。
SGs 和甜菊醇在所有测定的方面对 STZ 糖尿病小鼠均表现出抗糖尿病作用，具有诱导 SGs 开始发挥作用的时间。甜菊苷和甜菊醇可增加糖尿病小鼠心肌和脑组织对葡萄糖的摄取，并减少肝脏和肾脏中葡萄糖的积累。SGs 的性能强度通常与它们分子中的葡萄糖基数量一致。
